기사본문
OPTOLANE has signed MOU with ExoCobio for 'Exosome characteristics'
입력 2021-01-18 11:14 수정 2021-01-18 11:14
by Yoonseok Suh
OPTOLANE Technologies, Inc. and ExoCoBio Co., Ltd have signed the MOU for technology development based on Digital Real-time PCR platform for analysis of exosome characteristics on Jan, 14th.
According to the announcement, OPTOLANE and ExoCoBio have agreed to cooperate with the development of standardized analysis technology to overcome the limitations of the current analyzing technology of exosome characteristics and expedite the commercialization of disease diagnosis and therapeutics with exosomes.
OPTOLANE has developed a digital real-time PCR platform technology that operates digital real-time PCR on a semiconductor optical sensor. This technology can quantify the absolute number of gene copies in a specimen with the high sensitivity (0.01%).
In addition, OPTOLANE applies the digital real-time PCR platform to a characterization of diverse exosomes with one platform such as quantification of genes within exosomes and surface proteins of exosomes and characteristic analysis of exosomes secreted from stem cells of donors.
ExoCoBio is a company that develops functional cosmetics and atopic treatments base on exosomes. An exosome GMP facility in Osong, Chungbuk has been constructed to set mass production process for commercialization.
An official of OPTOLANE mentioned, “the key to this business cooperation is the development of an exosome characterization technology that helps the manufacturing process to produce exosomes with less variation through OPTOLANE’s digital real-time platform”.
